Septerna (NASDAQ:SEPN) Earns Buy Rating from Analysts at TD Cowen

TD Cowen began coverage on shares of Septerna (NASDAQ:SEPN) in a research note issued to investors on Tuesday, MarketBeat reports. The firm issued a buy rating on the stock.

Septerna Trading Down 3.2 %

Shares of Septerna stock opened at $21.79 on Tuesday. Septerna has a 52-week low of $18.62 and a 52-week high of $26.34.

Insider Buying and Selling

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the transaction, the insider now directly owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.